A5040710891- Pituitary Gland Disorders and Treatments
- Adrenal and Paraganglionic Tumors
- Neuroendocrine Tumor Research Advances
- Adrenal Hormones and Disorders
- Neuroblastoma Research and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Lung Cancer Research Studies
- Cancer, Hypoxia, and Metabolism
- Hormonal Regulation and Hypertension
- Glioma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Venous Thromboembolism Diagnosis and Management
- Erythrocyte Function and Pathophysiology
- Iron Metabolism and Disorders
- Gastrointestinal Tumor Research and Treatment
- Myasthenia Gravis and Thymoma
- Hemoglobinopathies and Related Disorders
- Stress Responses and Cortisol
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Electrolyte and hormonal disorders
- Cardiac tumors and thrombi
- Ophthalmology and Eye Disorders
- Erythropoietin and Anemia Treatment
- Parathyroid Disorders and Treatments
Erasmus MC
2016-2025
Erasmus MC Cancer Institute
2015-2025
NYU Langone Health
2025
European Neuroendocrine Tumor Society
2025
Erasmus University Rotterdam
2014-2024
Rotterdam University of Applied Sciences
1994-2023
Cancer Genomics Centre
2021-2023
Oregon Medical Research Center
2023
Radboud University Nijmegen
1994-2023
Buda Health Center
2023
Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs) are slow-growing, median overall survival (OS) in patients with liver metastases is 2 to 4 years. In metastatic disease, cytoreductive therapeutic options limited. A relatively new therapy peptide receptor radionuclide radiolabeled somatostatin analog [(177)Lu-DOTA(0),Tyr(3)]octreotate. Here we report on toxicity and efficacy of this treatment, performed over 500 patients.Patients were treated up a cumulative...
Purpose There are few treatment options for patients with metastasized or inoperable endocrine gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but the response is usually less than 1 year. Here, we present results of a radiolabeled somatostatin analog, [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate ( Lu-octreotate). Patients and Methods One hundred thirty-one receptor-positive tumors were treated up to cumulative dose 600 800 mCi (22.2 29.6 GBq) Lu-octreotate. Results patient...
Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These targets for therapy with Lutetium-177-labeled analogues. We have treated over 1,200 patients peptide receptor radionuclide (PRRT) [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) since the year 2000 present results efficacy, survival, toxicity of this therapy.Experimental Design: For safety analysis, 610 a cumulative...
Objective The European Registry on Cushing's syndrome (ERCUSYN) is designed to collect prospective and follow-up data at EU level (CS). Design methods Baseline 481 CS patients (390 females, 91 males; mean age (± s.d. ): 44±14 years) collected from 36 centres in 23 countries, including new 2008 retrospective cases since 2000. Patients were divided into four major aetiologic groups: pituitary-dependent (PIT-CS) (66%), adrenal-dependent (ADR-CS) (27%), an ectopic source (ECT-CS) (5%) other...
Recurrence of adrenocortical carcinoma (ACC) even after complete (R0) resection occurs frequently. The aim this study was to identify markers with prognostic value for patients in clinical setting. From the German ACC registry, 319 European Network Study Adrenal Tumors stage I–III were identified. As an independent validation cohort, 250 from three countries included. Clinical, histological, and immunohistochemical correlated recurrence-free (RFS) overall survival (OS). Although univariable...
Cross-sectional imaging regularly results in incidental discovery of adrenal tumours, requiring exclusion adrenocortical carcinoma (ACC). However, differentiation is hampered by poor specificity characteristics. We aimed to validate a urine steroid metabolomics approach, using profiling as the diagnostic basis for ACC.
The objective of this study was to establish recommendations for thromboprophylaxis in patients with endogenous Cushing's syndrome (CS), addressing the elevated risk venous thromboembolism (VTE) associated hypercortisolism. A Delphi method used, consisting 4 rounds voting and subsequent discussions. panel included 18 international experts from 11 countries continents. Consensus defined as ≥75% agreement among participants. Recommendations were structured into following categories:...
Context: Physiological changes in thyroid hormone concentrations might be related to the overall physical function elderly. Objective: We determined what extent are and mortality elderly men. Design: A longitudinal population study (the Zoetermeer study) was conducted. Mortality registered subsequent 4 yr. Participants: Four hundred three independently ambulatory living men (aged 73–94 yr) participated. Main Outcome Measures: The examined association between serum hormones parameters of as...
Objective : Currently, there is no effective medical treatment for patients with pituitary-dependent Cushing’s disease. A novel somatostatin (SS) analogue, named SOM230, high binding affinity to SS receptor subtypes sst 1 , 2 3 and 5 was recently introduced. We compared the in vitro effects of -preferring analogue octreotide (OCT) multi-ligand SOM230 on ACTH release by human mouse corticotroph tumour cells. Methods By quantitative RT-PCR subtype expression level determined adenomas. In...
Surgery on pheochromocytoma carries a risk for hemodynamic (HD) instability. The aim of this study was to identify preoperative factors intraoperative HD In addition, efficacy pretreatment with the alpha-adrenergic receptor (alpha) antagonists phenoxybenzamine (PXB) and doxazosin (DOX) compared respect reduction instability.Seventy-three patients operated in Erasmus Medical Center between 1995 2007 were included. Parameters studied catecholamine type concentration, tumor diameter, mean...
Venous thrombosis has frequently been reported in patients with endogenous Cushing's syndrome (CS).The aim of this study was to evaluate the incidence venous thromboembolism (VTE) CS prior treatment and after surgery.We conducted a multicenter cohort at all university medical centers The Netherlands.Consecutive diagnosed benign origin between January 1990 June 2010 were eligible for inclusion. Patients surgically treated nonfunctioning pituitary adenoma served as controls postoperative VTE...
To determine the inhibitory profile of novel somatostatin (SRIF) analog SOM230 with broad SRIF receptor binding, we compared in vitro effects SOM230, octreotide (OCT), and SRIF-14 on hormone release by cultures different types secreting pituitary adenomas. OCT (10 nm) significantly inhibited GH seven nine GH-secreting adenoma (range, −26 to −73%), eight −22 −68%), six −30 −75%). The sst analysis showed predominant but variable levels (sst)2 sst5 mRNA expression. In one culture completely...
The objective of the study was to assess whether weekly administration 40 mg pegvisomant (PEG-V) improves quality life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.This a prospective, investigator-initiated, double blind, placebo-controlled, crossover study. Twenty subjects received either PEG-V or placebo for two consecutive treatment periods 16 wk, separated by washout period 4...
Background: We previously reported the efficacy of a combined treatment active acromegaly with both long-acting somatostatin analogs (SSA) and pegvisomant (PEG-V).
Somatostatin receptor subtype 2 (sst2A) protein expression has been demonstrated to positively correlate with somatostatin analog treatment outcome in GH-secreting adenomas. Recently, a new rabbit monoclonal anti-sst2A antibody (clone UMB-1) validated as reliable method selectively detect sst2A levels formalin-fixed tissues. The aim of the study was establish whether evaluation levels, assessed routine reproducible immunohistochemistry protocol using UMB-1 antibody, may predict successful...
Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC). A correlation between mitotane patient outcome has not demonstrated an adjuvant setting.To compare recurrence-free (RFS) who reached maintained 1 4 vs did not.Retrospective analysis at six referral European centers.Patients ACC were radically resected 1995 2009 treated adjuvantly targeting of 14-20 mg/l.RFS (primary) overall...